Edition:
India

Pacira Pharmaceuticals Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

41.20USD
10:56pm IST
Change (% chg)

$-0.30 (-0.72%)
Prev Close
$41.50
Open
$41.45
Day's High
$41.80
Day's Low
$40.95
Volume
38,537
Avg. Vol
187,616
52-wk High
$58.80
52-wk Low
$29.90

Chart for

About

Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product... (more)

Overall

Beta: 2.08
Market Cap(Mil.): $1,474.48
Shares Outstanding(Mil.): 40.34
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.11 16.44
EPS (TTM): -- -- --
ROI: -- 14.85 10.61
ROE: -- 16.31 14.21

BRIEF-Wellstar And Pacira To Minimize Opioid Use Across Surgical Procedures

* WELLSTAR HEALTH SYSTEM AND PACIRA PHARMACEUTICALS ANNOUNCE PARTNERSHIP TO MINIMIZE OPIOID USE AND STANDARDIZE OUTCOMES ACROSS SURGICAL PROCEDURES Source text for Eikon: Further company coverage:

08 Jan 2018

BRIEF-Pacira Pharmaceuticals Reports Preliminary 2017 Revenues Of $286.6 Million

* PACIRA PHARMACEUTICALS REPORTS PRELIMINARY 2017 REVENUES OF $286.6 MILLION

04 Jan 2018

BRIEF-Pacira announces FDA advisory committee meeting to review sNDA for Exparel

* Pacira announces FDA advisory committee meeting to review sNDA for Exparel as a nerve block for regional analgesia

14 Nov 2017

BRIEF-Pacira Pharmaceuticals reports Q3 non-gaap earnings per share $0.11

* Pacira Pharmaceuticals Inc reports third quarter 2017 financial results

08 Nov 2017

BRIEF-Pacira Pharma to invest up to $25 million in Tela Bio

* Committed to invest up to $25 million in Tela Bio, a privately-held surgical reconstruction company​

25 Oct 2017

BRIEF-Pacira Pharmaceuticals announces FDA acceptance of SNDA

* Pacira Pharmaceuticals announces FDA acceptance of SNDA for exparel as a nerve block to produce regional analgesia

18 Oct 2017

BRIEF-‍Point72 Asset Management LP reports a 5 pct passive stake in Pacira Pharmaceuticals ​

* ‍Point72 Asset Management LP reports a 5.0 pct passive stake in Pacira Pharmaceuticals Inc as of Aug 21 - SEC filing ​ Source text: (http://bit.ly/2io69IV) Further company coverage:

23 Aug 2017

BRIEF-Healthcor Management L.P.‍ reports a 6.2 pct passive stake in Pacira Pharmaceuticals

* Healthcor Management L.P.‍ reports a 6.2 pct passive stake in Pacira Pharmaceuticals, as of Aug 3 - SEC filing ​ Source text for Eikon: (http://bit.ly/2fEM3Jn) Further company coverage:

14 Aug 2017

BRIEF-Pacira Pharma says data on Exparel published in medical journal

* Pacira announces publication of phase 4 study of exparel in patients undergoing total knee replacement in the journal of arthroplasty Source text for Eikon: Further company coverage:

26 Jul 2017

BRIEF-Pacira announces topline phase 3 results for Exparel

* Pacira announces topline phase 3 results for Exparel as a single-dose nerve block

25 Jul 2017

Competitors

Earnings vs. Estimates